Number of Initial Refills for VIBERZI 100 mg Twice Daily
Provide 3-6 months of refills (3-6 refills) initially when prescribing VIBERZI 100 mg twice daily, as this is a chronic medication for IBS-D that requires ongoing treatment and has demonstrated sustained efficacy through 26 weeks in clinical trials.
Rationale Based on FDA Label and Clinical Evidence
The FDA-approved prescribing information for VIBERZI indicates this is a maintenance medication for irritable bowel syndrome with diarrhea (IBS-D) that requires continuous use 1. Clinical trials demonstrated:
Efficacy maintained throughout 6 months of treatment - Studies showed composite response rates remained consistent from month 1 through month 6, with no evidence of tolerance or diminishing effect 1
No withdrawal symptoms - The 4-week placebo withdrawal period in Study 2 showed no worsening of diarrhea or abdominal pain compared to baseline, indicating this is not a medication requiring tapering 1
Chronic disease management - IBS-D is a chronic condition requiring ongoing symptom control, not acute treatment 1
Practical Prescribing Approach
Initial prescription strategy:
- Write for a 30-day supply (60 tablets total - one tablet twice daily)
- Authorize 3-6 refills to provide 4-7 months of medication
- This allows adequate time to assess therapeutic response while ensuring treatment continuity
Monitoring schedule per FDA guidance:
- Patients should be assessed for efficacy after the first month of treatment
- Continue monitoring for adverse effects, particularly constipation and abdominal pain
- If severe constipation develops, discontinue immediately 1
Important Safety Considerations
When providing refills, counsel patients to:
- Stop immediately and seek medical attention if unusual or severe abdominal pain develops (potential pancreatitis risk) 1
- Avoid chronic alcohol use while taking VIBERZI 1
- Not take missed doses by doubling up - simply resume at the next scheduled time 1
- Discontinue if severe constipation occurs 1
The 3-6 month refill approach balances the need for ongoing chronic disease management with appropriate safety monitoring intervals, while research shows that compliance generally improves with fewer refill requirements 2, 3.